$1.39
+2.3%Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
STIM • NASDAQ
| Neuronetics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
149.2M | 74.9M | 71.3M | 65.2M | 55.3M | 49.2M | 62.7M | 52.8M | 40.4M | 34.2M | |
GROSS PROFIT | ||||||||||
(76.8M) | (20.7M) | (19.6M) | (15.5M) | (11.7M) | (11.6M) | (15.4M) | (12.4M) | (9.6M) | (6.6M) | |
72.3M | 54.2M | 51.7M | 49.7M | 43.7M | 37.7M | 47.3M | 40.3M | 30.8M | 27.6M | |
OPERATING INCOME | ||||||||||
(103.7M) | (88.7M) | (82.3M) | (84.8M) | (71.2M) | (60M) | (74.2M) | (60.2M) | (44.4M) | (36.9M) | |
(97.2M) | (76M) | (72.7M) | (75.5M) | (63.3M) | (50.8M) | (60.5M) | (51.9M) | (36.5M) | (28.7M) | |
(6.6M) | (12.8M) | (9.5M) | (9.3M) | (7.9M) | (9.2M) | (13.7M) | (8.2M) | (7.9M) | (8.2M) | |
-31.4M | -34.6M | -30.6M | -35.1M | -27.6M | -22.3M | -26.9M | -19.8M | -13.6M | -9.3M | |
PRE-TAX INCOME | ||||||||||
(8.4M) | (7.3M) | (5.4M) | (3.6M) | (3.3M) | (4.5M) | (3.7M) | (3.7M) | (2.8M) | (1.8M) | |
-8.4M | -7.3M | -5.4M | -3.6M | -3.3M | -4.5M | -3.7M | -3.7M | -2.8M | -1.8M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -575K | (357K) | -62K | |
-7.6M | -9.2M | 365K | -2.1M | -3.6M | -5.1M | -2.1M | -4.3M | -2.5M | -1.9M | |
-39M | -43.7M | -30.2M | -37.2M | -31.2M | -27.5M | -29M | -24.1M | -16.1M | -11.2M | |
NET INCOME | ||||||||||
(0.0) | -14K | -24K | (0.0) | (0.0) | (0.0) | (5.3M) | (0.0) | (0.0) | (0.0) | |
-39M | -43.7M | -30.2M | -37.2M | -31.2M | -27.5M | -34.3M | -24.1M | -16.1M | -11.2M |
STIM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 22, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 09, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 06, 2026 | March 31, 2026 | 2026 | |
S-3 S-3 N/A | March 17, 2026 | March 17, 2026 | ||
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 |
Continue your STIM research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.